5 Most Promising Cancer Stocks According to Wall Street Analysts

2. Cardiff Oncology, Inc. (NASDAQ:CRDF)

Price Target Upside: 395.87%

Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list.

TheFly reported on June 5 that Lucid Capital analyst Christopher Liu reduced the price target on CRDF to $4 from $10 while reaffirming a Buy rating. The revised target reflected uncertainty surrounding an ongoing licensing dispute with Nerviano Medical Sciences involving ownership rights to onvansertib. Despite the legal overhang, the firm believes both companies have strong incentives to resolve the issue in the near future. Lucid Capital also indicated that investor attention could shift back to Cardiff’s clinical progress, with future onvansertib data potentially catalyzing a recovery in the company’s share price.

In addition to that, on June 2, Cardiff Oncology, Inc. (NASDAQ:CRDF) reported data from the Phase 2 CRDF-004 trial evaluating onvansertib with standard chemotherapy in first-line RAS-mutated metastatic colorectal cancer. The 30 mg onvansertib plus FOLFIRI/bevacizumab regimen, selected for Phase 3 development, delivered stronger tumor responses and longer progression-free survival than standard treatment without increasing safety concerns. The combination achieved a 72.2% confirmed objective response rate versus 42.1% for standard therapy alone. Following discussions with the FDA, the company finalized the design of its registrational Phase 3 study, which will evaluate the same regimen as first-line treatment for patients with RAS-mutated metastatic colorectal cancer.

Cardiff Oncology, Inc. (NASDAQ:CRDF) is a clinical-stage biotechnology company developing precision cancer therapies, led by onvansertib, a PLK1 inhibitor designed to overcome treatment resistance.